Mirum Pharmaceuticals, Inc. (MIRM)

In May 2026, Mirum reported strong first-quarter financial results and raised its full-year net product sales guidance. The company also announced positive topline results from the Phase 2b VISTAS study of volixibat and the Phase 2b portion of the AZURE-1 study of brelovitug. In January 2026, Mirum completed the acquisition of Bluejay Therapeutics, impacting Q1 operating expenses. In February 2026, the company's stock fell following the disclosure of a share offering. Mirum reported its fourth-quarter and full-year 2025 results, with a significant increase in total net product sales.

Historically, Mirum Pharmaceuticals has observed some seasonality in its international Livmarli sales, with the first quarter typically being softer. However, in Q1 2026, this seasonality was less pronounced due to strong performance in additional countries and the increasing presence of PFIC sales internationally.

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases, particularly rare liver and neurodevelopmental conditions. Its portfolio includes Livmarli for cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis, Cholbam for bile acid synthesis disorders, and Ctexli for cerebrotendinous xanthomatosis. The company's clinical-stage pipeline includes volixibat for primary sclerosing cholangitis and primary biliary cholangitis, brelovitug for chronic hepatitis delta virus, zilurgisertib for fibrodysplasia ossificans progressiva, and MRM-3379 for Fragile X syndrome.

Mirum Pharmaceuticals has a global presence with approved products and a commercial footprint that extends to over 30 countries across North America and Europe.

Mirum Pharmaceuticals maintains a positive brand reputation within the rare disease community due to its focus on developing therapies for overlooked conditions and its strong connections with patient communities. Recent positive clinical trial results have further bolstered its scientific and development reputation. Analyst ratings for MIRM stock are largely positive, with a consensus of "Strong Buy".

Mirum Pharmaceuticals' ownership is predominantly institutional, with major shareholders including Frazier Life Sciences Management, L.P., Janus Henderson Group Plc, BlackRock, Inc., Vanguard Group Inc, and State Street Corp. Joshua Makower is the largest individual shareholder.